Skip to content

Advertisement

  • Poster presentation
  • Open Access

Raltegravir clinical efficacy against B subtype and non-B subtype HIV-1 is similar

  • ,
  • 2,
  • 1,
  • 1,
  • 1,
  • 1 and
  • 1
Journal of the International AIDS Society200811 (Suppl 1) :P207

https://doi.org/10.1186/1758-2652-11-S1-P207

  • Published:

Keywords

  • Efavirenz
  • Raltegravir
  • Integrase Inhibitor
  • Identical Phase
  • P004 Result

Purpose of the study

Raltegravir (RAL) is the first approved HIV integrase inhibitor and has demonstrated potent efficacy in both treatment-experienced and -naïve HIV-infected patients (pts). This analysis reports long-term efficacy data from one Phase II and two Phase III studies in pts infected with non-B subtype virus.

Methods

Each study was double-blind and randomized; all pts received a background ART regimen (see table in Figure 1). Primary results have been presented for each study. Protocol (P) 004 in treatment-naïve pts was a dose-ranging study of RAL vs. efavirenz (EFV) until week 48 after which all pts in RAL groups received 400 mg BID. BENCHMRK-1 and -2 were identical Phase III studies using RAL at 400 mg BID vs. placebo (PBO) in highly treatment-experienced pts with multi-drug resistant virus failing other therapies. Each of the three studies showed potent clinical efficacy for RAL-treated pts. In this analysis, P004 results are shown for all RAL dose groups combined at week 96, and BENCHMRK-1 and -2 results are shown combined at week 48. Non-B subtypes were combined for the analyses due to small numbers of each specific non-B subtype.
Figure 1
Figure 1

Percent of pts with HIV RNA <50 copies/ml.

Summary of results

In total, 622 pts were randomized to RAL and 275 to comparator across the three studies. Non-B subtype virus was isolated at baseline in 62 pts in the RAL groups (23 from P004), and in 23 pts in the comparator groups (8 from P004). Subtypes AE and D were most common, isolated in 40 and eight pts, respectively. Data are available for 58/62 and 22/23 of pts with non-B subtype virus using the observed failure approach for % with RNA < 50 copies/mL (see table in Figure 1). RAL-treated pts demonstrated increases from baseline in CD4 of 216 and 250 cells/mm3 for B and non-B, respectively, at week 96 in P004, and of 105 and 150 cells/mm3, for B and non-B, respectively, at week 48 in BENCHMRK-1 and -2.

Conclusion

In these studies, RAL showed similar and potent clinical efficacy in patients with B subtype and non-B subtype HIV in both treatment-naïve and treatment-experienced populations.

Authors’ Affiliations

(1)
Merck & Co., Inc., North Wales, PA, USA
(2)
University of Bonn, Bonn-Venusberg, Germany

Copyright

© Teppler et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Advertisement